The difference between fundraising by private biopharmaceutical companies and publicly traded drug developers has been stark in 2022. In fact, the last few days of June were emblematic of the long lag between plunging stock prices and their impact on venture capital.
In the same week that ARCH Venture Partners raised a $2.975bn venture capital fund – 27 June to 1 July...